Pharmacogenomics of intravenous immunoglobulin response in Kawasaki disease Dr. Michael Portman recently presented findings from a groundbreaking study on Kawasaki disease (KD) at the Seattle Children’s Hospital KD Clinic. The study involved a whole genome sequencing of hundreds of...
KD Aneurysm & Transition of Care A group of experts led by Dr. Tremoulet from the Kawasaki Disease Research Center at the University of California, San Diego has published a manuscript through the American Heart Association. The manuscript highlights...
Pharmacy alumni and faculty work with research team to develop North America’s first test to predict Kawasaki disease A new tool under development by University at Buffalo researchers could one day help clinicians better predict resistance to immunoglobulin therapy...
MIS-C and KD are on the same immune response continuum as COVID-19 A recent study revealed that MIS-C and KD are on the same immune response continuum as COVID-19, with MIS-C being a more severe version of the response...
Infliximab versus second intravenous immunoglobulin for treatment of resistant Kawasaki disease in the USA (KIDCARE): a randomised, multicentre comparative effectiveness trial Summary Background Although intravenous immunoglobulin (IVIG) is effective therapy for Kawasaki disease, 10–20% of patients have recrudescent fever...
Same Treatment Tested for Kids with Kawasaki Disease and Rare COVID-19 Reaction In a pair of new studies, published online October 26 and August 31, 2021, two collaborating teams of researchers at University of California San Diego School of...
Researcher: Kawasaki Disease Spike In San Diego Likely Tied To Aerosol Particles An unusual and potentially deadly disease is making a growing number of San Diego County children sick, and researchers say it’s caused by something in the air....
Fever, conjunctivitis, rash, and belly pain KD case study written by two medical doctors highlights that children with KD and prominent GI (gastrointestinal (GI) symptoms of abdominal pain and diarrhea) or hepatobiliary (having to do with the liver plus...
Treatment Intensification in Patients With Kawasaki Disease and Coronary Aneurysm at Diagnosis Coronary artery aneurysms (CAA) are a serious complication of Kawasaki disease. Treatment with intravenous immunoglobulin (IVIg) within 10 days of fever onset reduces the risk of CAA...
Etanercept With IVIg for Acute Kawasaki Disease: A Randomized Controlled Trial Dr. Michael A. Portman and colleagues have published the results of a clinical trial showing benefits by etanercept (brand name Enbrel) for Kawasaki Disease patients. The results were...